OBJECTIVE: Rheumatoid arthritis (RA) is thought to be a T cell-mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to T cell-directed therapies, and the presence of CD4+ T cells in rheumatoid joints. The presence of anti-citrullinated protein antibodies (ACPAs) in RA serum and the association of these antibodies with HLA-DR4 alleles implicate citrulline-specific autoreactive T cells in the development and progression of RA. The goal of this study was to determine the characteristics and specificity of autoreactive T cell responses in RA. METHODS: We developed a panel of HLA-DRB1*04:01 tetramers, selecting citrullinated peptides from synovial antigens and verifying their immunogenicity in DRB1*04:01-transgenic mice. Seven tetramers were used to examine the ex vivo frequency and surface phenotype of citrulline-specific (Cit-specific) T cells in patients with RA and healthy subjects with DRB1*04:01 haplotypes, using a magnetic enrichment procedure. RESULTS: Cit-specific T cells were detectable in peripheral blood samples from both healthy subjects and RA patients. In comparison to healthy subjects, RA patients had significantly higher frequencies of Cit-specific T cells, and a greater proportion of these cells displayed a Th1 memory phenotype. Among RA patients, the frequency of Cit-specific T cells was highest within the first 5 years after diagnosis of RA and was decreased in patients taking biologic agents, irrespective of disease duration. CONCLUSION: These findings link the presence of ACPAs in RA with Th1 cells specific for citrullinated epitopes and provide tools for disease-specific immunomonitoring of autoreactive T cells.
OBJECTIVE:Rheumatoid arthritis (RA) is thought to be a T cell-mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to T cell-directed therapies, and the presence of CD4+ T cells in rheumatoid joints. The presence of anti-citrullinated protein antibodies (ACPAs) in RA serum and the association of these antibodies with HLA-DR4 alleles implicate citrulline-specific autoreactive T cells in the development and progression of RA. The goal of this study was to determine the characteristics and specificity of autoreactive T cell responses in RA. METHODS: We developed a panel of HLA-DRB1*04:01 tetramers, selecting citrullinated peptides from synovial antigens and verifying their immunogenicity in DRB1*04:01-transgenic mice. Seven tetramers were used to examine the ex vivo frequency and surface phenotype of citrulline-specific (Cit-specific) T cells in patients with RA and healthy subjects with DRB1*04:01 haplotypes, using a magnetic enrichment procedure. RESULTS: Cit-specific T cells were detectable in peripheral blood samples from both healthy subjects and RApatients. In comparison to healthy subjects, RApatients had significantly higher frequencies of Cit-specific T cells, and a greater proportion of these cells displayed a Th1 memory phenotype. Among RApatients, the frequency of Cit-specific T cells was highest within the first 5 years after diagnosis of RA and was decreased in patients taking biologic agents, irrespective of disease duration. CONCLUSION: These findings link the presence of ACPAs in RA with Th1 cells specific for citrullinated epitopes and provide tools for disease-specific immunomonitoring of autoreactive T cells.
Authors: James J Moon; H Hamlet Chu; Marion Pepper; Stephen J McSorley; Stephen C Jameson; Ross M Kedl; Marc K Jenkins Journal: Immunity Date: 2007-08-16 Impact factor: 31.745
Authors: Ruth A Ettinger; George K Papadopoulos; Antonis K Moustakas; Gerald T Nepom; William W Kwok Journal: J Immunol Date: 2006-02-01 Impact factor: 5.422
Authors: Erik Wambre; Jonathan H DeLong; Eddie A James; Rebecca E LaFond; David Robinson; William W Kwok Journal: J Allergy Clin Immunol Date: 2011-10-05 Impact factor: 10.793
Authors: Soumya Raychaudhuri; Cynthia Sandor; Eli A Stahl; Jan Freudenberg; Hye-Soon Lee; Xiaoming Jia; Lars Alfredsson; Leonid Padyukov; Lars Klareskog; Jane Worthington; Katherine A Siminovitch; Sang-Cheol Bae; Robert M Plenge; Peter K Gregersen; Paul I W de Bakker Journal: Nat Genet Date: 2012-01-29 Impact factor: 38.330
Authors: Andreas E R Fasth; Omri Snir; Anna A T Johansson; Birgitta Nordmark; Afsar Rahbar; Erik Af Klint; Niklas K Björkström; Ann-Kristin Ulfgren; Ronald F van Vollenhoven; Vivianne Malmström; Christina Trollmo Journal: Arthritis Res Ther Date: 2007 Impact factor: 5.156
Authors: Karim Raza; Francesco Falciani; S John Curnow; Emma J Ross; Chi-Yeung Lee; Arne N Akbar; Janet M Lord; Caroline Gordon; Christopher D Buckley; Mike Salmon Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Cliff Rims; Hannes Uchtenhagen; Mariana J Kaplan; Carmelo Carmona-Rivera; Philip Carlucci; Katalin Mikecz; Adrienn Markovics; Jeffrey Carlin; Jane H Buckner; Eddie A James Journal: Arthritis Rheumatol Date: 2019-03-08 Impact factor: 10.995
Authors: Yi Tian Ting; Jan Petersen; Sri H Ramarathinam; Stephen W Scally; Khai L Loh; Ranjeny Thomas; Anish Suri; Daniel G Baker; Anthony W Purcell; Hugh H Reid; Jamie Rossjohn Journal: J Biol Chem Date: 2018-01-09 Impact factor: 5.157
Authors: Jennifer Pieper; Anatoly Dubnovitsky; Christina Gerstner; Eddie A James; Mary Rieck; Genadiy Kozhukh; Karolina Tandre; Sara Pellegrino; John A Gebe; Lars Rönnblom; Tatyana Sandalova; William W Kwok; Lars Klareskog; Jane H Buckner; Adnane Achour; Vivianne Malmström Journal: J Autoimmun Date: 2018-05-28 Impact factor: 7.094
Authors: Anca I Catrina; Camilla I Svensson; Vivianne Malmström; Georg Schett; Lars Klareskog Journal: Nat Rev Rheumatol Date: 2016-12-15 Impact factor: 20.543
Authors: Joerg Ermann; Deepak A Rao; Nikola C Teslovich; Michael B Brenner; Soumya Raychaudhuri Journal: Nat Rev Rheumatol Date: 2015-06-02 Impact factor: 20.543
Authors: Manon A A Jansen; Rachel Spiering; Femke Broere; Jacob M van Laar; John D Isaacs; Willem van Eden; Catharien M U Hilkens Journal: Immunology Date: 2017-09-18 Impact factor: 7.397